Skip to content

Replimune

US · REPL #3130 by market cap Listed 2018
19.07 -0.16 -0.83%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 18.90 -1.72%
After-hours 19.09 +0.10%
Overnight 19.33 +0.52%
23.284.6019.072026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on REPL?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +73.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 26.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → B

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Return on equity -107.9% Better than 5%
Return on invested capital -79.3% Better than 3%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 29.1% Better than 98%
6-month return 288.4% Better than 100%
12-month return (ex latest month) 30.3% Better than 69%
Distance below 52-week high 19.0% Better than 63%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.8x Better than 85%
Debt to assets 33.6% Better than 35%
Interest coverage -34.5x Better than 8%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 25.9% Better than 42%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -12.88%
1M +66.99%
3M +35.73%
6M +269.57%
YTD +96.19%
1Y +111.65%
3Y +87.33%
5Y -44.32%

Key statistics

Price & volume

Prev close
19.23
Open
18.84
Day range
18.69 - 19.50
Avg price
19.00
Volume
1.96M
Turnover
37.33M
Amplitude
4.21%
52-week range
1.50 - 23.54

Valuation

P/E
-5.64
P/E (TTM)
-6.84
P/B
8.83
EPS
-3.38
Net profit
-320.43M
Net assets
204.77M

Share structure

Market cap
1.81B
Float cap
1.25B
Shares out
94.80M
Float shares
65.56M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2018-07-20
52-week range 80% of range
1.50 23.54

19.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-27.55M net over the window

Short interest

Shares short
24.61M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Replimune (REPL)?

Replimune last traded at 19.07. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Replimune's market cap?

About 1.81B.

What is the P/E ratio of Replimune?

The trailing twelve-month P/E is -6.84. The Valuation tab shows it against the stock's own five-year range.

Does Replimune pay a dividend?

Replimune does not currently pay a regular dividend.

Is Replimune a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 24.00, which implies 25.9% upside from the current price. This is not investment advice.

What is Replimune's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Replimune a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:01:05 · For reference only, not investment advice and not tailored to your situation.

Replimune discussion 0 comments

Add a comment